Key facts
- This page summarizes Daniel E. Geffken's Form 4 filing for CalciMedica, Inc. (CALC).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 May 2023, 20:59.
Daniel E. Geffken - 20 Mar 2023 Form 4 Insider Report for CalciMedica, Inc. (CALC)
- Reporting relationship
- Interim CFO
- Issuer ticker
- CALC
- Reported as of
- 20 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 May 2023, 20:59:51 UTC
- Prior SEC filing
- 07 Jul 2022
- Next SEC filing
- 29 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- By John Dunn, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel E. Geffken filed Form 4 for CalciMedica, Inc. (CALC) on 03 May 2023.
Change
- Previous filing in this sequence was filed on 07 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CALC
transaction
Derivative
Warrant
Award
- Transaction value
- Shares
- +11,520
- Change %
- Price
- Shares after
- 11,520
- Date
- 20 Mar 2023
- Ownership
- By SG Dan Equity Holdings, LLC
- Underlying class
- Common Stock
- Underlying amount
- 11,520
- Exercise price
- $6.60
- Footnotes
- F1, F2
CALC
transaction
Derivative
Warrant
Award
- Transaction value
- Shares
- +5,760
- Change %
- Price
- Shares after
- 5,760
- Date
- 20 Mar 2023
- Ownership
- By SG Dan Equity Holdings, LLC
- Underlying class
- Common Stock
- Underlying amount
- 5,760
- Exercise price
- $10.42
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Immediately exercisable.
Footnote F2
Received in exchange for a warrant to acquire 400,000 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding warrant to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into a warrant to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
Footnote F3
Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. Upon the closing of the Merger, each outstanding warrant to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into a warrant to purchase the Issuer's common stock